Shortened therapy for genotype 1 hepatitis C virus. The final answer?
Journal Title: Annals of Hepatology - Year 2010, Vol 9, Issue 1
Abstract
Background & Aims. In hepatitis C virus genotype 1 (HCV-1) patients with a rapid viral decline within the first month of therapy, a 24-week course of pegylated interferon (PEG-IFN) alpha and ribavirin treatment has been claimed to be as efficient as the standard 48-week duration. Methods. We performed a meta-analysis of 7 randomized controlled trials comparing less than 48 weeks to 48 weeks PEG-IFN alpha/ribavirin treatment in 807 HCV-1 patients with rapid viral decline. Results. SVR was significantly less frequent with short treatment duration than with 48 weeks of therapy, with a mean difference of -13.6% (95% CI: -22.8% to -4.4%, p = 0.004). This difference was related to a higher relapse rate (mean difference: 9.9%, 95% CI: 4.1.15.7%, p < 0.001). In a sensitivity analysis restricted to studies using only a weight-based ribavirin regimen, shorter therapy was also less efficient. In the subgroup of patients with undetectable HCV-RNA at week 4 and a low baseline HCV-RNA level (≤400,000 IU/mL), there was no significant difference in SVR rates between 24 and 48 weeks of treatment (mean difference: -3.10%, 95% CI: -8.6% to 2.4%, NS). Conclusions. In HCV-1 patients with a rapid virological response, 24 weeks of combination therapy with PEG-IFN alpha and ribavirin should be considered only in subjects with low baseline viral load. However, the optimal cut-off defining low baseline viral load and the impact of the presence of other factors capable of altering treatment response, remain subject to debate.
Authors and Affiliations
Francisco Barrera M, Alejandro Soza
Keywords
Related Articles
- EP ID EP77923
- DOI -
- Views 115
- Downloads 0
Does the size of the needle influence the number of portal tracts obtained through percutaneous liver biopsy?
Aim. Liver biopsy (LB) is often essential for the diagnosis and staging of chronic viral hepatitis. The aim of our paper was to establish if the size of the biopsy needle influences the number of portal tracts obtained...
Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C
Background and rationale. The REPLACE study (NCT01571583) investigated telaprevir-based triple therapy in patients whohave recurrent genotype 1 hepatitis C virus (HCV) infection following liver transplantation and are o...
Portal vein thrombosis in patients with cirrhosis: just a common finding or a predictor of poor outcome?
Background & Aims. It is unclear whether portal vein thrombosis (PVT) unrelated to malignancy is associated with reduced survival or it is an epiphenomenon of advanced cirrhosis. The objective of this study...
Clinical characteristics of liver failure from a systemic cause: A report from an advanced critical care center
Background/Purpose. In Japan, acute liver failure (ALF) has generally been described using the diagnostic term, “fulminant hepatitis”, because of the fact that most cases of ALF has been thought to occur in association...
Alcohol use among patients with HIV infection
Objective. To evaluate alcohol use in patients with HIV infection, assess ethnic and social associations, and describe outcomes. Material and methods. Design: cohort study. Setting: Academic HIV-Liver Clinic. Patients: 4...